News | CT Angiography (CTA) | October 16, 2018

CT Offers Non-Invasive Alternative for Coronary Disease Treatment Planning

Heart teams find CT angiography equally beneficial to angiography when deciding between treatment options

CT Offers Non-Invasive Alternative for Complex Coronary Disease Treatment Planning

October 16, 2018 — A new study published in the European Heart Journal[1] shows computed tomography (CT) can be a useful aid in heart team decision-making for complex coronary disease. Results also suggest the state-of-the-art imaging technology may offer a non-invasive diagnostic alternative to conventional coronary angiography. Coronary artery disease (CAD) and its complications are a leading cause of death throughout the world.[2] According to therapeutic guidelines, left main or three vessel diseases represent the most severe, high-risk CAD cases, often requiring coronary bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) as treatment.[3]

The international, multicenter SYNTAX III Revolution trial – conducted by Cardialysis on behalf of the European Cardiovascular Research Institute (ECRI) – included 223 subjects with diagnosed left main or three vessel disease. Each patient was diagnosed using conventional, invasive angiography and subsequently received a multislice CT scan on the 512-slice GE Healthcare Revolution CT. Data from each subject was evaluated by two randomized heart teams – each made up of an interventional cardiologist, cardiac surgeon and radiologist – to make a treatment recommendation of CABG, PCI or either. One heart team made treatment recommendations based only on the coronary CT angiography (CTA) imaging, and the other made treatment recommendations using angiography. Based on the trial’s findings, the treatment decisions between the two randomized heart teams were in almost perfect agreement (Cohen’s kappa of 0.82). These results highlight the potential of CT to not only diagnose coronary disease, but also assist in subsequent heart team decision-making.

“The implications of these trial results for the future are tremendous,” said Prof. Patrick W. Serruys, principal investigator and study chairman. “In the next five to ten years, with its increasing accuracy, I think we are going to see the new generation of multislice CT scans play an increasingly important role in diagnosing and treating CAD. It will take time and it will take multiple trials, but the results of our SYNTAX III trial suggest a promising, real change in our practice.”

This change could include streamlining the care pathway. The multislice CT scan offers an easier, less-invasive patient experience; takes less time; and a provides a clear, comprehensive anatomical picture to assist clinicians with diagnoses and treatment recommendations. Serruys suggests the CT’s potential as a diagnostic tool for complex coronary disease could enable cath labs to transition from diagnostic to interventional suites that concentrate on the significant load of coronary and structural heart disease patients.

“Technological advancements are drastically improving medical insights and opportunities as well as patient care,” continued Serruys. “The ability to capture an image of the whole heart in one beat with the multislice CT and then see the coronary artery from multiple views is very appealing to interventional cardiologists and surgeons. The images provided by the multislice CT are a bonus that can help surgeons plan and mentally prepare to treat patients in the interventional suite.”

After reviewing the trial’s results, 84 percent of surveyed[4] cardiac surgeons agreed planning and executing surgery based on the multislice CT scan is viable. Cardialysis will follow up the SYNTAX III Revolution trial with a new study, CABG Revolution, to test the safety of CABG surgery for left main or three vessel disease using only the anatomy and function described by the multislice CT scan.

The SYNTAX III trial is an investigator-driven study sponsored by the ECRI and funded by research grants from GE Healthcare and HeartFlow Inc.

For more information: www.academic.oup.com/eurheartj

 

References

[1] Collet C., Onuma Y., Andreini D., et al. Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. European Heart Journal, Oct. 11, 2018. https://doi.org/10.1093/eurheartj/ehy581

[2] Gersh B.J, Sliwa K., Mayosi B.M., Yusuf S. “Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.” European Heart Journal. 2010 Mar; 31(6):642-8.https://www.ncbi.nlm.nih.gov/pubmed/20176800/

[3] Mohr F.W., Morice M.C., Kappetein A.P., et al. “Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.” Lancet. 2013 Feb 23; 381(9867):629-38. https://www.ncbi.nlm.nih.gov/pubmed/23439102/

[4] Cardialysis. “Theoretical Feasibility of Planning CABG based only on Coronary CTA and FFRCT: A Survey of the Surgeons involved in the Randomized Syntax III Revolution Trial.” 2018 Jan. Unpublished raw data.

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Brazil's Santa Casa Hospital System Chooses Carestream for Unified Diagnostic Workflow
News | PACS | May 22, 2019
Santa Casa de Misericordia has selected Carestream to replace its legacy diagnostic workflow technology across all...
Philips Lumify Earns U.S. Army Airworthiness Certification
News | Ultrasound Imaging | May 22, 2019
Philips announced that Philips Lumify, a point-of-care ultrasound device, has earned the U.S. Army Airworthiness...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Computer-Aided Detection Software | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
Life Image and Bialogics Analytics Partner to Deliver Imaging Business Intelligence
News | Analytics Software | May 21, 2019
Life Image and business intelligence analytics provider Bialogics Analytics have formed a strategic partnership that...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
AI Detects Unsuspected Lung Cancer in Radiology Reports, Augments Clinical Follow-up
News | Artificial Intelligence | May 20, 2019
Digital Reasoning announced results from its automated radiology report analytics research. In a series of experiments...
Videos | Digital Radiography (DR) | May 20, 2019
This is a quick walk-around video showing the ...